Indegene Q2 FY27 Revenue Surges 39.5% YoY to ₹11,223M; H1 USD Revenue Up 27% YoY
Indegene's Q2 FY27 revenue grew 39.5% YoY to ₹11,223 million ($117.5M). H1 FY27 USD revenue increased 27.0% YoY. EBITDA was ₹1,873 million (16.7% margin) and PAT was ₹1,123 million (10.0% margin). The company saw an increase in $1M+ clients to 59 and expects continued growth and margin expansion.
Significant year-on-year revenue growth and profit improvement are material events for investors and stakeholders.
The company reported strong revenue growth, increased client base, and healthy profit margins, indicating positive financial performance.
Indegene Limited announced its financial results for the second quarter and half year ended September 30, 2026, with the Board of Directors approving the results in a meeting held on October 29, 2026. The company reported a strong performance, with Q2 FY27 revenue reaching ₹11,223 million ($117.5 million), marking a year-on-year (YoY) increase of 39.5% in INR and 27.5% in USD. This represents the fifth consecutive quarter of revenue growth above 5% sequentially in INR. The growth was broad-based, driven by expansion across its top accounts and an increase in the number of clients generating over $1 million annually to 59. The company also highlighted significant deal wins in GenAI-enabled transformation and upstream engagements.
EBITDA for the quarter stood at ₹1,873 million, with an EBITDA margin of 16.7%, up 32.0% YoY, despite wage hikes. Profit After Tax (PAT) was ₹1,123 million, a 10.0% YoY increase, with a profit margin of 10.0%. The company noted that the EBITDA margin remained largely stable, and with wage increases now fully reflected, expects EBITDA to grow faster than revenue in the coming quarters. Higher investment yields and lower amortization are also expected to help PAT margin expand faster than EBITDA margin. Revenue per Employee (RPE) further strengthened to $79.6K, which the company claims is the highest among peers. Indegene, a strategic operating partner to the global life sciences industry, continues to leverage its deep expertise and AI-embedded platforms to deliver measurable outcomes.
What to do with a filing like this
Indegene Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indegene Limited. Read the original for the full detail.